|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These results suggest that the 5-HT1A receptor gene is intact in mood disorders.
|
7612160 |
1995 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Converging evidence from postmortem studies of mood disorders suggests these reductions of 5HT1A receptor BP may be associated with histopathological changes involving the raphe.
|
10578452 |
1999 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Genetic variation at the 5HT1A and 5HT2C receptor genes does not, therefore, play a major role in the pathogenesis of mood disorders symptomatology.Am.J. Med.Genet.(Neuropsychiatr.Genet.)96:161-166, 2000.
|
10893489 |
2000 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings.
|
15458611 |
2004 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Alterations in 5-HT(1A,) 5-HT(1B), and 5-HT(2A) mRNA levels in the brains of subjects with both mood disorders and schizophrenia add further support for hypothesis of dysregulation of the serotonergic system in these psychiatric disorders.
|
14744462 |
2004 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alterations in 5-HT(1A,) 5-HT(1B), and 5-HT(2A) mRNA levels in the brains of subjects with both mood disorders and schizophrenia add further support for hypothesis of dysregulation of the serotonergic system in these psychiatric disorders.
|
14744462 |
2004 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Dysfunction of the serotonin (5-HT1A) receptor (5-HTR1A) has been implicated in mood disorders, anxiety disorders, psychosis and the action of antidepressants.
|
15469667 |
2004 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
5-HT 1A polymorphism and self-transcendence in mood disorders.
|
15952185 |
2005 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
LHGDN |
We tested involvement of 5-HT(1A) gene in this trait, in a sample of 40 remitted mood disorder patients.
|
15952185 |
2005 |
|
Mood Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Alterations in 5-HT1A receptor levels are implicated in mood disorders, and a functional C(-1019)G 5-HT1A promoter polymorphism has been associated with depression, suicide, and panic disorder.
|
16467535 |
2006 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These results indicate an important (mainly inhibitory) role of galanin as a regulator of brain serotonin and 5-HT1A receptor-mediated transmission, which may be of potential importance for understanding mood disorders and for the development of antidepressant drugs.
|
16863269 |
2006 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
5-HT1A gene variants have been reported to play some role in mood disorders, anxiety disorders and psychotic disorders.
|
18047755 |
2008 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Gene-gene interaction studies suggest that the 5-HT1A receptor G(-1019) allele is a risk allele which could be used as a marker for depression and related mood disorders.
|
18639564 |
2008 |
|
Mood Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Altered expression of serotonin-1A (5-HT1A) receptors, both presynaptic in the raphe nuclei and post-synaptic in limbic and cortical target areas, has been implicated in mood disorders such as major depression and anxiety.
|
19423080 |
2009 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Three genes contributed exclusively to mood disorders, one through a main effect (HTR5A (rs1657268)) and two through gene-environment interactions with CPA (HTR1A (rs878567) and SLC6A4 (rs3794808)).
|
19381154 |
2010 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
PSYGENET |
Due to its modulatory effect on serotonin (5-HT) release, the 5-HT(1A)-receptor is thought to play a decisive role in the therapy of this mood disorder.
|
21419787 |
2011 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Serotonin (5-hydroxytryptamine, 5-HT) neurotransmission is negatively regulated by 5-HT1A autoreceptors on raphe neurons, and is implicated in mood disorders.
|
21182526 |
2011 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
PSYGENET |
Altered regulation of the serotonin-1A (5-HT1A) receptor gene is implicated in major depression and mood disorders.
|
22232550 |
2012 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
PSYGENET |
Results from this expanded meta-analysis, which included our own new study, suggest that rs6295 (C-1019G) and rs878567 in HTR1A are related to the pathophysiology of MDs, with overlap between MDD and BP.
|
22752684 |
2013 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Results from this expanded meta-analysis, which included our own new study, suggest that rs6295 (C-1019G) and rs878567 in HTR1A are related to the pathophysiology of MDs, with overlap between MDD and BP.
|
22752684 |
2013 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
PSYGENET |
In MDD, however, the effect of the val66met polymorphism is not detectable, possibly due to a ceiling effect of over-expression of 5-HT(1A) receptors in mood disorders.
|
24607934 |
2014 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In MDD, however, the effect of the val66met polymorphism is not detectable, possibly due to a ceiling effect of over-expression of 5-HT(1A) receptors in mood disorders.
|
24607934 |
2014 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
PSYGENET |
RGS6 is enriched in hippocampal and cortical neurons, 5-HT(1A)R-expressing cells implicated in mood disorders.
|
24421401 |
2014 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The clinical implications of targeting alexithymia and HTR1A receptors as a possible treatment option for mood disorders should be investigated in further studies.
|
26609890 |
2015 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
This study suggests that serotonin signaling through postsynaptic 5-HT1A receptors in the hippocampus is critical for the antidepressant-like effects of a cholinergic drug and begins to elucidate the molecular mechanisms underlying interactions between the serotonergic and cholinergic systems related to mood disorders.
|
25288485 |
2015 |